Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias

250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.

A. Dunbar, L. Gondek, C. O'keefe, et al.. (2008). Cancer research. Cited 309 times. https://doi.org/10.1158/0008-5472.CAN-08-2754

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.

M. Sekeres, W. Schoonen, H. Kantarjian, et al.. (2008). Journal of the National Cancer Institute. Cited 266 times. https://doi.org/10.1093/jnci/djn349

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

M. Sekeres, P. Elson, M. Kalaycio, et al.. (2009). Blood. Cited 217 times. https://doi.org/10.1182/blood-2008-05-157065

Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects.

K. Uchida, K. Nakata, Takuji Suzuki, et al.. (2009). Blood. Cited 105 times. https://doi.org/10.1182/blood-2009-05-155689

Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates.

T. Sakagami, D. Beck, K. Uchida, et al.. (2010). American journal of respiratory and critical care medicine. Cited 93 times. https://doi.org/10.1164/rccm.201001-0008OC

TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p

M. Jasek, L. Gondek, N. Bejanyan, et al.. (2009). Leukemia. Cited 82 times. https://doi.org/10.1038/leu.2009.189

Response: Granulocyte/macrophage colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy persons.

K. Uchida, B. Carey, Takuji Suzuki, et al.. (2009). Blood. Cited 72 times. https://doi.org/10.1182/blood-2009-11-246041

Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes

A. Golshayan, T. Jin, J. Maciejewski, et al.. (2007). British Journal of Haematology. Cited 69 times. https://doi.org/10.1111/j.1365-2141.2007.06546.x

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome

J. Zou, D. Rollison, D. Boulware, et al.. (2009). Leukemia. Cited 68 times. https://doi.org/10.1038/leu.2009.14

Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.

P. Epling-Burnette, L. Sokol, Xianhong Chen, et al.. (2008). Blood. Cited 52 times. https://doi.org/10.1182/blood-2008-02-136382

Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia

S. Mohan, M. Clemente, M. Afable, et al.. (2009). Haematologica. Cited 40 times. https://doi.org/10.3324/haematol.2009.009191

Immunogenetic factors determining the evolution of T‐cell large granular lymphocyte leukaemia and associated cytopenias

Z. Nearman, M. Wlodarski, A. Jankowska, et al.. (2007). British Journal of Haematology. Cited 32 times. https://doi.org/10.1111/j.1365-2141.2006.06429.x

A Decision analysis to determine the appropriate treatment for low‐risk myelodysplastic syndromes

M. Sekeres, A. Fu, J. Maciejewski, et al.. (2007). Cancer. Cited 28 times. https://doi.org/10.1002/cncr.22497

Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia.

M. Wlodarski, Z. Nearman, Ying Jiang, et al.. (2008). Experimental hematology. Cited 25 times. https://doi.org/10.1016/j.exphem.2007.11.011

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.

S. Nyland, D. Krissinger, M. Clemente, et al.. (2012). Leukemia research. Cited 14 times. https://doi.org/10.1016/j.leukres.2012.02.001

Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

M. Sekeres, D. Steensma. (2009). Blood. Cited 13 times. https://doi.org/10.1182/blood-2009-06-228114